Atea Pharmaceuticals, Inc. Common Stock
AVIR Real Time Price USDRecent trades of AVIR by members of U.S. Congress
|
Name
|
Type
|
Shares
|
Price
|
Shares Held
|
Date
|
Reported
|
|---|
|
Investor
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
|
Investor
|
Type
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
Recently reported changes by institutional investors
Quarterly net insider trading by AVIR's directors and management
Government lobbying spending instances
-
$30,000 Apr 22, 2024 Issue: Budget/Appropriations Medical/Disease Research/Clinical Labs
-
$30,000 Apr 21, 2024 Issue: Medical/Disease Research/Clinical Labs Health Issues
-
$30,000 Jan 22, 2024 Issue: Budget/Appropriations Medical/Disease Research/Clinical Labs
-
$50,000 Jan 20, 2024 Issue: Medical/Disease Research/Clinical Labs Health Issues
-
$50,000 Oct 23, 2023 Issue: Medical/Disease Research/Clinical Labs Health Issues
-
$30,000 Oct 20, 2023 Issue: Budget/Appropriations Medical/Disease Research/Clinical Labs
-
$30,000 Jul 20, 2023 Issue: Budget/Appropriations Medical/Disease Research/Clinical Labs
-
$50,000 Jul 20, 2023 Issue: Medical/Disease Research/Clinical Labs Health Issues
-
$50,000 Jan 20, 2023 Issue: Medical/Disease Research/Clinical Labs Health Issues
-
$30,000 Jan 19, 2023 Issue: Budget/Appropriations Medical/Disease Research/Clinical Labs
-
$10,000 Nov 02, 2022 Issue: Health Issues
-
$30,000 Oct 21, 2022 Issue: Medical/Disease Research/Clinical Labs Health Issues
-
$30,000 Oct 19, 2022 Issue: Budget/Appropriations Medical/Disease Research/Clinical Labs
-
$10,000 Aug 08, 2022 Issue: Health Issues
-
$30,000 Jul 19, 2022 Issue: Budget/Appropriations Medical/Disease Research/Clinical Labs
-
$10,000 May 09, 2022 Issue: Health Issues
-
$30,000 Apr 19, 2022 Issue: Medical/Disease Research/Clinical Labs Budget/Appropriations
-
$10,000 Feb 09, 2022 Issue: Health Issues
-
$30,000 Jan 18, 2022 Issue: Budget/Appropriations Medical/Disease Research/Clinical Labs
-
$20,000 Nov 19, 2021 Issue: Health Issues
-
$30,000 Oct 19, 2021 Issue: Budget/Appropriations Medical/Disease Research/Clinical Labs
-
$20,000 Aug 05, 2021 Issue: Health Issues
-
$30,000 Jul 08, 2021 Issue: Budget/Appropriations Medical/Disease Research/Clinical Labs
-
$20,000 May 03, 2021 Issue: Health Issues
-
$30,000 Apr 15, 2021 Issue: Medical/Disease Research/Clinical Labs Budget/Appropriations
-
$20,000 Feb 03, 2021 Issue: Health Issues
-
$30,000 Jan 20, 2021 Issue: Budget/Appropriations Medical/Disease Research/Clinical Labs
-
$20,000 Nov 05, 2020 Issue: Health Issues
-
$30,000 Oct 16, 2020 Issue: Medical/Disease Research/Clinical Labs Budget/Appropriations
-
$20,000 Aug 04, 2020 Issue: Health Issues
-
$30,000 Jul 16, 2020 Issue: Medical/Disease Research/Clinical Labs Budget/Appropriations
Estimated quarterly lobbying spending
AVIR Revenue by Segment or Geography
New patents grants
Federal grants, loans, and purchases
Estimated quarterly amount awarded from public contracts
Recent insights relating to AVIR
Recent picks made for AVIR stock on CNBC
ETFs with the largest estimated holdings in AVIR
- ... Highest Price Target
- ... Median Price Target
- ... Lowest Price Target
|
Analyst
|
Firm
|
Current
|
Previous
|
Date
|
|---|
- Is $AVIR stock a Buy, Sell, or Hold?
- What is the price target for $AVIR stock?
* Analyst consensus is not financial advice. Please see our data disclaimers .
|
Shareholder
|
Shares Held
|
|---|
- Who owns $AVIR stock?
- Who owns the most shares of $AVIR stock?
- What funds own $AVIR stock?
* These are estimates based on data taken from SEC filings. There may be inaccuracies due to parsing errors, accidental double-counting, incorrect classification of indirectly owned shares, or any other number of issues.
The Quiver Smart Score combines our data on Congress Trading, Lobbying, Insider Trading, CNBC Mentions and more to provide a comprehensive view of the strength of a stock's underlying data.
The Smart Score grades stocks on a scale of 1 (weakest) to 10 (strongest) based on the strength of the underlying data.Sign Up to view AVIR Smart Score
See concise summaries of analyst reports, presenting both bullish and bearish arguments for a stock.
Example:
The Bulls Say summary highlights positive aspects of the stock.
The Bears Say summary points out potential risks and negative aspects of the stock.